Donanemab Slows Progression in Early Alzheimer’s
AMSTERDAM -- Investigational donanemab significantly slowed clinical progression at 76 weeks in people with early…
Browsing Tag
Donanemab
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of…
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.Cristina Arias | Cover | Getty ImagesEli Lilly on Monday said it applied for full U.S. Food and Drug…
Donanemab Slows Cognitive, Functional Decline in Early Alzheimer’s
Much of the discussion at the American Academy of Neurology annual meeting centered on a…
Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical…
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.Mike Segar | ReutersThe Alzheimer's treatment donanemab,…
Donanemab Analyses Suggest Benefits for Select Alzheimer’s Patients
Baseline amyloid levels predicted amyloid plaque response with donanemab, an investigational…